Filtern
Volltext vorhanden
- ja (24)
Gehört zur Bibliographie
- ja (24)
Erscheinungsjahr
Dokumenttyp
Sprache
- Englisch (24)
Schlagworte
- B cells (3)
- adalimumab (3)
- rheumatoid arthritis (3)
- scleroderma (3)
- systemic sclerosis (3)
- Autologous hematopoietic stem cell transplantation (2)
- Systemic sclerosis (2)
- Th17 (2)
- antirheumatic agents (2)
- inflammation (2)
- memory B cells (2)
- regression analysis (2)
- treatment outcome (2)
- B cell culture (1)
- CMV reactivation (1)
- CP-690,550 (1)
- Clinical remission (1)
- DAS28 (1)
- DMARD (1)
- Drug-free remission (1)
- GCA (1)
- GRAID (1)
- Grave’s disease (1)
- HAQ (1)
- Infectious complications (1)
- Interleukin-10 (1)
- Medizin (1)
- Memory B cells (1)
- PMR (1)
- PROM’s (1)
- PU.1 (1)
- Rheumatoid Arthritis (1)
- Rituximab (1)
- S100A8/S100A9 (1)
- Scleroderma (1)
- Sjögren’s syndrome (1)
- Synovitis (1)
- T cells (1)
- Th9 (1)
- Tregs (1)
- Validation (1)
- [18F]FDG PET/CT (1)
- adverse events (1)
- arthritis (1)
- autoimmune disease (1)
- autoimmune encephalitis (1)
- autoimmunity (1)
- autologous hematopoietic stem cell transplantation (1)
- autologous stem cell transplantation (1)
- bile (1)
- c-reactive protein (1)
- calprotectin (1)
- care (1)
- chemokines (1)
- cirrhosis (1)
- clinical-practice (1)
- common variable immunodeficiency (1)
- common variable immunodeficiency (CVID) (1)
- contrast-enhanced ultrasound. (1)
- cytokines (1)
- cytotoxic T cells (1)
- discordance (1)
- disease comorbidities (1)
- disease-activity score (1)
- engraftment syndrome (1)
- fatigue (1)
- fever (1)
- genital warts (1)
- giant cell arteritis (1)
- health-assessment questionnaire (1)
- hepatitis C virus (1)
- human papillomavirus (1)
- immune cells (1)
- immunophenotyping (1)
- immunosuppression (1)
- inborn errors of immunity (IEIs) (1)
- inflammation marker (1)
- interleukin-9 (1)
- iohexol (1)
- janus kinase inhibitor (1)
- kidney function (1)
- liver diseases (1)
- methotrexate (1)
- methylation (1)
- minimally important difference (1)
- modified Rodnan skin score (mRSS) (1)
- mycophenolate (1)
- naïve B cells (1)
- neurology (1)
- physicians (1)
- plasma clearance (1)
- polymyalgia rheumatica (1)
- primary immunodeficiencies (1)
- primary immunodeficiency (1)
- renal function (1)
- renal perfusion (1)
- reported outcomes (1)
- rheumatoid (1)
- rheumatoid arhritis (1)
- risk factor analysis (1)
- rituximab (1)
- serum creatinine (1)
- suppression (1)
- tocilizumab (1)
- tocilizumab (IL-6 inhibitor) (1)
- validation (1)
- vasculature (1)
- vasculitis (1)
- γδ T cells (1)
Institut
- Medizinische Klinik und Poliklinik II (24)
- Kinderklinik und Poliklinik (3)
- Neurologische Klinik und Poliklinik (2)
- Frauenklinik und Poliklinik (1)
- Institut für Humangenetik (1)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (1)
- Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie (1)
- Klinik und Poliklinik für Nuklearmedizin (1)
- Pathologisches Institut (1)
Several studies have shown that tapering or stopping disease-modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis (RA) patients in sustained remission is feasible. However, tapering/stopping bears the risk of decline in physical function as some patients may relapse and face increased disease activity. Here, we analyzed the impact of tapering or stopping DMARD treatment on the physical function of RA patients. The study was a post hoc analysis of physical functional worsening for 282 patients with RA in sustained remission tapering and stopping DMARD treatment in the prospective randomized RETRO study. HAQ and DAS-28 scores were determined in baseline samples of patients continuing DMARD (arm 1), tapering their dose by 50% (arm 2), or stopping after tapering (arm 3). Patients were followed over 1 year, and HAQ and DAS-28 scores were evaluated every 3 months. The effect of treatment reduction strategy on functional worsening was assessed in a recurrent-event Cox regression model with a study-group (control, taper, and taper/stop) as the predictor. Two-hundred and eighty-two patients were analyzed. In 58 patients, functional worsening was observed. The incidences suggest a higher probability of functional worsening in patients tapering and/or stopping DMARDs, which is likely due to higher relapse rates in these individuals. At the end of the study, however, functional worsening was similar among the groups. Point estimates and survival curves show that the decline in functionality according to HAQ after tapering or discontinuation of DMARDs in RA patients with stable remission is associated with recurrence, but not with an overall functional decline.